BMEA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BM

Mkt Cap

$62.8M

Volume

3.67M

Next Earnings

November 3rd

Loading chart

BM

BMEABiomea Fusion, Inc. Common Stock

BMEA

Pay with—

Available Balance0.00

BM

Mkt Cap

$60.6M

Volume

3.67M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 StudyBiomea Fusion presented clinical and translational data for icovamenib at the ADA 86th Scientific Sessions, demonstrating improvements in HbA1c and C-peptide levels in type 1 and type 2 diabetes patients, along with potential benefits for muscle preservation and fat reduction. The company also expanded its Phase I BMF-650 study to evaluate rapid titration schedules for its oral GLP-1 receptor agonist candidate.GlobeNewswire Inc. · Jun 5, 2026

Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate HighlightsBiomea Fusion reported Q1 2026 net loss of $12.4 million, down significantly from $29.3 million in Q1 2025, driven by reduced R&D and G&A expenses following headcount reductions. The company announced positive 52-week data from its Phase II COVALENT-112 trial showing icovamenib achieved a 52% increase in C-peptide levels in recently diagnosed type 1 diabetes patients with durability through Week 52. Two Phase II type 2 diabetes trials (COVALENT-211 and COVALENT-212) are enrolling with topline data expected in Q4 2026, while the Phase I obesity trial (GLP-131) is on track with initial weight reduction data expected in Q2 2026. Cash runway is projected into Q1 2027.GlobeNewswire Inc. · May 11, 2026

Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific SessionsBiomea Fusion announced that three abstracts on icovamenib, its investigational oral menin inhibitor, have been selected for late-breaking poster presentations at the ADA 86th Scientific Sessions in June 2026. The presentations will showcase data from Phase 2 trials (COVALENT-111 and COVALENT-112) demonstrating icovamenib's potential to improve beta cell function and insulin secretion in both type 1 and type 2 diabetes patients, including those on background GLP-1 therapy.GlobeNewswire Inc. · May 5, 2026

Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care TherapiesBiomea Fusion announced the first patient dosing in two Phase II clinical trials (COVALENT-211 and COVALENT-212) evaluating icovamenib for type 2 diabetes patients failing standard-of-care therapies. COVALENT-211 targets insulin-deficient T2D patients, while COVALENT-212 targets patients uncontrolled on GLP-1 receptor agonists. Both studies will enroll approximately 60 patients each, with topline 26-week primary endpoint data anticipated in Q4 2026. The trials build on positive Phase II COVALENT-111 data showing durable HbA1c reductions of up to 1.8% that persisted nine months post-treatment.GlobeNewswire Inc. · Mar 31, 2026

Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026Biomea Fusion announced positive 52-week follow-up results from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes patients. The drug demonstrated durable efficacy nine months post-dosing, with severe insulin-deficient diabetes patients achieving a 1.2% HbA1c reduction at Week 52. The company maintained a favorable safety profile and plans to advance two new Phase II studies targeting specific patient populations.GlobeNewswire Inc. · Mar 14, 2026

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025Dr. Ralph DeFronzo presented insights on icovamenib, a potential disease-modifying therapy for diabetes, highlighting its ability to restore beta cell mass and function through menin inhibition during the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.GlobeNewswire Inc. · Dec 9, 2025

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025Biomea Fusion will present two poster presentations at ObesityWeek® 2025, highlighting preclinical data for BMF-650, an oral GLP-1 receptor agonist, and combination data for icovamenib with semaglutide.GlobeNewswire Inc. · Oct 30, 2025

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat SeriesBiomea Fusion, a clinical-stage diabetes and obesity company, will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on October 23, 2025, offering a live audio webcast of the discussion.GlobeNewswire Inc. · Oct 21, 2025

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Biomea Fusion granted a new employee non-qualified stock options to purchase 48,000 shares of common stock, with shares vesting quarterly over four years under the company's 2023 Inducement Equity Plan.GlobeNewswire Inc. · Oct 1, 2025

Biomea Fusion (BMEA) Q2 Loss Drops 44%Biomea Fusion reported a reduced net loss of $20.7 million in Q2 2025, down from $37.3 million in the same period of 2024. The biotechnology company focused on metabolic disease treatments showed progress in cost management and clinical development of its lead drug icovamenib for diabetes and potential obesity treatments.The Motley Fool · Aug 6, 2025

to start trading

BM

BMEABiomea Fusion, Inc. Common Stock

BMEA

Pay with—

Available Balance0.00

Your PositionYou don't own any BMEA yet.

Related Tickers

Earnings